Pharmacopsychiatry

Papers
(The TQCC of Pharmacopsychiatry is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
144
Challenges Related to the Implementation of Measurement-Based Care for the Treatment of Major Depressive Disorder: A Feasibility Study53
Increased Odds of Cognitive Impairment in Adults with Depressive Symptoms and Antidepressant Use45
Early Treatment-Resistance in First Episode Psychosis23
5-HTTLPR-rs25531 and Antidepressant Treatment Outcomes in Korean Patients with Major Depression20
Pharmacological Treatment of Autism Spectrum Disorder: A Systematic Review of Treatment Guidelines18
Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice16
Therapeutic Drug Monitoring of Cariprazine – Updated Values for a Dose-Related Reference Range16
Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study15
14
Association between Adherence to SSRI Treatment and Mortality among Individuals with Metabolic Syndrome Components14
The Therapeutic Potential of Pimavanserin in the Treatment of Hallucinogen Induced Psychosis and Persistent Perceptual Symptoms13
The Role of Circadian Rhythmicity and CLOCK Genes in Psychiatry13
Valproic Acid Induced Thrombocytopenia in an Elderly Man with Schizoaffective Disorder: A Case Report13
Human Derived Dermal Fibroblasts as in Vitro Research Tool to Study Circadian Rhythmicity in Psychiatric Disorders12
Challenges and Ethical Considerations to Successfully Implement Artificial Intelligence in Clinical Medicine and Neuroscience: a Narrative Review11
Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine 10
An Oppositional Tolerance Account for Potential Cognitive Deficits Caused by the Discontinuation of Antidepressant Drugs9
Clinical Outcomes after Clozapine Discontinuation in Patients with Schizophrenia: A Systematic Review9
Twenty-Three Years of Declining Lithium Use: Analysis of a Pharmacoepidemiological Dataset from German-Speaking Countries9
Exposure to Psychotropic Drugs and Colorectal Cancer Risk in Patients with Affective Disorder: A Nested Case-Control Study8
Selective Serotonin Reuptake Inhibitors may Influence COVID-19 Prognosis through Antioxidant and Cytoprotective Pathways Mediated by Sigma 1 Receptor Agonism8
2001–2021 Comparative Persistence of Oral Antipsychotics in Patients Initiating Treatment: Superiority of Clozapine in Time-to-Treatment Discontinuation7
Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 Stu6
Comparable Psychotropic Prescription Rates After Hospital Discharge Between Patients with COVID-19 and Those With Non-COVID-19-Related Respiratory Infection6
Effectiveness of Medical Cannabis for the Treatment of Depression: A Naturalistic Outpatient Study5
Implications of Online Self-Diagnosis in Psychiatry5
Blood Cell Count Ratios at Baseline are Associated with Initial Clinical Response to Clozapine in Treatment-Resistant, Clozapine-Naïve, Schizophrenia-Spectrum D5
Augmentation of Electroconvulsive Therapy with Oral Caffeine: A Retrospective Analysis of 40 Patients with Major Depression5
5
SARS-CoV-2-Infection in People Addicted to Illegal Drugs – Is There a Protective Effect of Opioid Maintenance Treatment?5
„AGNP-Preis für Forschung in der Psychopharmakologie“ in Höhe von 5.000 €4
COVID-19: Risks, Complications, and Monitoring in Patients on Clozapine4
The Role of Mood Stabilizers in Children and Adolescents with Anorexia Nervosa: A 1-year Follow-Up, Propensity Score-Matched Study4
Baseline Working Memory Predicted Response to Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression4
4
Life-time Actionable Pharmacogenetic Drug Use: A Population-based Cohort Study in 86 040 Young People With and Without Mental Disorders in Denmark4
Strategies and Management for Psychiatric Drug Withdrawal: A Systematic Review of Case Reports and Series4
3
The Mini-TRH Test3
Overview: Chronic Pain and Cannabis-Based Medicines3
The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics3
Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments3
Correction: Electroconvulsive Therapy Versus Aripiprazole Addition to Clozapine in Patients with Clozapine-Resistant Symptoms (EMECLO): A Protocol of a Single-Blind, Multicenter, R3
Does Lidocaine Shorten Seizure Duration in Electroconvulsive Therapy?3
Cannabinoids for Behavioral Symptoms in Dementia: An Overview3
0.22012901306152